tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VSTM Stock Latest News

Verastem price target lowered to $14 from $16 at Mizuho
The FlyVerastem price target lowered to $14 from $16 at Mizuho
3d ago
VSTM
Closing Bell Movers: Coherent down 18% as earnings miss
PremiumThe Fly
Closing Bell Movers: Coherent down 18% as earnings miss
4d ago
DLO
STN
Verastem Unveils Promising VS-7375 Study Results
PremiumCompany Announcements
Verastem Unveils Promising VS-7375 Study Results
4d ago
8K
VSTM
Verastem’s VS-7375 shows efficacy in lung cancer
PremiumThe Fly
Verastem’s VS-7375 shows efficacy in lung cancer
4d ago
VSTM
Verastem Inc. Earnings Call: Positive Outlook with Key Achievements
PremiumCompany Announcements
Verastem Inc. Earnings Call: Positive Outlook with Key Achievements
5d ago
VSTM
Verastem’s Promising Phase 3 Study in Ovarian Cancer: A Potential Game-Changer?
PremiumCompany AnnouncementsVerastem’s Promising Phase 3 Study in Ovarian Cancer: A Potential Game-Changer?
10d ago
VSTM
Verastem files $300M mixed securities shelf
Premium
The Fly
Verastem files $300M mixed securities shelf
10d ago
VSTM
Verastem’s Promising Market Expansion and Financial Health Drive Buy Rating
Premium
Ratings
Verastem’s Promising Market Expansion and Financial Health Drive Buy Rating
10d ago
VSTM
Verastem Oncology’s Q2 2025 Financial and Business Highlights
PremiumCompany Announcements
Verastem Oncology’s Q2 2025 Financial and Business Highlights
10d ago
VSTM
Verastem reports Q2 EPS (39c) vs. (31c) last year
PremiumThe Fly
Verastem reports Q2 EPS (39c) vs. (31c) last year
10d ago
VSTM
VSTM Earnings this Week: How Will it Perform?
PremiumPre-Earnings
VSTM Earnings this Week: How Will it Perform?
13d ago
VSTM
Verastem’s Phase 3 Study: A New Hope for Ovarian Cancer Treatment
PremiumCompany Announcements
Verastem’s Phase 3 Study: A New Hope for Ovarian Cancer Treatment
18d ago
VSTM
Verastem’s Phase 3 Study Update: A Potential Game-Changer in Ovarian Cancer Treatment
PremiumCompany AnnouncementsVerastem’s Phase 3 Study Update: A Potential Game-Changer in Ovarian Cancer Treatment
25d ago
VSTM
Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment
Premium
Company Announcements
Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment
1M ago
VSTM
Verastem publishes RAMP 201 trial data in Journal of Clinical Oncology
Premium
The Fly
Verastem publishes RAMP 201 trial data in Journal of Clinical Oncology
1M ago
VSTM
Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment
PremiumCompany Announcements
Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment
1M ago
VSTM
Verastem’s Promising Phase 3 Study on Recurrent Ovarian Cancer
PremiumCompany Announcements
Verastem’s Promising Phase 3 Study on Recurrent Ovarian Cancer
2M ago
VSTM
Verastem announces Nature Medicine publication of FRAME results
PremiumThe Fly
Verastem announces Nature Medicine publication of FRAME results
2M ago
VSTM
Verastem’s Promising Phase 3 Study on Avutometinib and Defactinib in Ovarian Cancer
PremiumCompany Announcements
Verastem’s Promising Phase 3 Study on Avutometinib and Defactinib in Ovarian Cancer
2M ago
VSTM
Verastem price target lowered to $12 from $16 at RBC Capital
PremiumThe FlyVerastem price target lowered to $12 from $16 at RBC Capital
2M ago
VSTM
Closing Bell Movers: FedEx slips 5% after results and guidance
Premium
The Fly
Closing Bell Movers: FedEx slips 5% after results and guidance
2M ago
BB
FDX
Verastem announces first patient dosed with VS-7375
Premium
The Fly
Verastem announces first patient dosed with VS-7375
2M ago
VSTM

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >